

ADTC (M) 23/01  
Minutes 01 - 09

**NHS GREATER GLASGOW AND CLYDE**

**Minutes of the Meeting of the  
Area Drugs and Therapeutics Committee  
held on Monday 20<sup>th</sup> February 2023 at 2.00pm  
via Microsoft Teams**

**PRESENT**

Dr Scott Muir (in the Chair)

Dr Maureen Byrne	Ms Sarah Jack
Ms Yvonne Clark	Dr Alister Maclaren
Mr Alexander Crichton	Ms Elaine McIvor
Ms Hannah Duncan	Prof Gerard McKay
Mr Roy Foot	Ms Mairi-Anne McLean
Dr Gordon Forrest	Ms Aileen Muir
Dr Roger Hardman	Dr Raymund White
Ms Stephanie Hart	Ms Audrey Thompson

**IN ATTENDANCE**

Ms Pamela Metcalfe	..	Secretariat (Minute)
Ms Sara Khalil		Secretariat

			<b>ACTION BY</b>
<b>01.</b>	<b>CHAIR'S STATEMENT</b>		
	<p>The Chair reminded members that papers and proceedings related to SMC advice were, in some cases, confidential, and should not be disclosed before the relevant embargo dates.</p> <p>Members were reminded to make relevant declarations of interest in line with Board policy.</p> <p>Members were advised not to speak with members of the press on ADTC business but to refer such enquiries to the Board Press Liaison Office.</p> <p><b><u>NOTED</u></b></p>		
<b>02.</b>	<b>WELCOME AND APOLOGIES</b>		
	<p>The Chair welcomed those present to the February meeting of the Area Drugs and Therapeutics Committee.</p>		

			<b>ACTION BY</b>
	<p>Apologies for absence were intimated on behalf of:</p> <ul style="list-style-type: none"> <li>• Elaine Paton</li> <li>• Judith Simpson</li> <li>• Janice Watt</li> </ul> <p><b><u>NOTED</u></b></p>		
<b>03.</b>	<b>MINUTES OF PREVIOUS MEETING</b>		
	<p>The Committee considered the minute of the meeting held on Monday 12<sup>th</sup> December 2022 [Paper No. ADTC (M) 22/05] and were content to accept this as an accurate record.</p> <p><b><u>APPROVED</u></b></p>		
<b>04.</b>	<b>MATTERS ARISING</b>		
	<p>Ms Hannah Duncan shared the presentation 'Liraglutide Update' [Paper 23/02]</p> <p>Ms Duncan shared an overview of the Liraglutide Update which highlighted the key area's below:</p> <ul style="list-style-type: none"> <li>• SMC Restricted Use</li> <li>• Prevalence of Potential candidates</li> <li>• Proposed pathway</li> <li>• Resources, Questions and Contact Details</li> </ul> <p>In response to the question regarding the volume of patient referrals received every month, Ms Duncan advised 100-130 however noted only 10-13 referrals were eligible for the drug.</p> <p><b><u>NOTED</u></b></p>		
<b>05.</b>	<b>NEW MEDICINES FOR CONSIDERATION</b>		
<b>(1)</b>	<b><u>REPORT ON SMC PRODUCT ASSESSMENTS</u></b>		
	<p>Members were asked to declare any interests specific or non-specific, personal or non-personal, on any of the drugs being discussed on an individual basis.</p> <p>No declarations of interest were made.</p>		

			<b>ACTION BY</b>
	<i>See Appendix 1 for summarised decisions.</i>		
	<b><u>NOTED</u></b>		
<b>(2)</b>	<b>WEST OF SCOTLAND CANCER NETWORK PRESCRIBING ADVISORY SUBGROUP REPORTS – DECEMBER 2022</b>		
	The Committee noted the West of Scotland Cancer Network Prescribing Advisory Subgroup Reports for December 2022 [Paper 23/04] for awareness.		
	<b><u>NOTED</u></b>		
<b>06.</b>	<b>ADTC SUBCOMMITTEE SIX MONTHLY REPORTS</b>		
<b>a)</b>	<b>Medicines Utilisations Subcommittee</b>		
	Dr Raymund White presented the paper 'Medicines Utilisation Subcommittee Six Month Report' [Paper 23/05].  The Committee noted the update report which provided a summary of the work undertaken by the Subcommittee over the last six months. The key focus remained on: <ul style="list-style-type: none"> <li>• Guidelines/Protocols</li> <li>• Clinical Effectiveness/Medicine Education Projects</li> <li>• GGC Therapeutics Handbook</li> <li>• Adult Medicines Formulary Management Issues</li> </ul> The Committee were content to note the update provided.		
	<b><u>NOTED</u></b>		
<b>b)</b>	<b>Non-Medicines Utilisation Subcommittee</b>		
	Ms Mairi-Anne McLean presented the paper 'Non-Medicines Utilisation Subcommittee Six Month Report' [Paper 23/06].  The Committee noted the update report which provided a summary of the work undertaken by the Subcommittee over the last six months. The key focus remained on: <ul style="list-style-type: none"> <li>• Formulary Status</li> <li>• Guideline Status</li> <li>• Reporting on Formulary Compliance</li> <li>• Subcommittee barriers encountered over the last 6 months</li> </ul>		

			<b>ACTION BY</b>
	The Committee noted the update provided.  <b><u>NOTED</u></b>		
<b>c)</b>	<b>Antimicrobial Subcommittee</b>		
	Dr Beth White presented the paper 'Antimicrobial Subcommittee Six Month Report' [Paper 23/07].  The Committee noted the update report which provided a summary of the work undertaken by the Subcommittee over the last six months. The key focus remained on: <ul style="list-style-type: none"> <li>• Meeting National Targets</li> <li>• Temocillin Use</li> <li>• Infection Management guidelines update</li> </ul> The Committee noted the update provided.		
	<b>ADTC SUBCOMMITTEE UPDATES</b>		
<b>a)</b>	<b>Safer Use of Medicines Subcommittee</b>		
	Prof Gerry McKay provided a verbal update on 'Safer Use of Medicines Subcommittee'  No update given.  <b><u>NOTED</u></b>		
<b>b)</b>	<b>Communications Subcommittee</b>		
	Mrs Elaine Mclvor provided a verbal update on 'Communications Subcommittee'  Mrs Mclvor noted the committee continued to meet every 4 weeks with the main focus being Junior Doctor targeted promotion.  Mrs Mclvor advised of a series of upcoming blogs related to Insulin safety.  <b><u>NOTED</u></b>		
	<b>PROGRESS UPDATES</b>		
<b>07.</b>	<b>HEPMA PROGRESS REPORT</b>		

OFFICIAL SENSITIVE

			<b>ACTION BY</b>
	The Committee noted the HEPMA progress report [Paper 23/08] submitted for awareness.  <b><u>NOTED</u></b>		
<b>08.</b>	<b>AOCB</b>		
	The Chair invited members to raise any other items of business.  There were no items of Business raised.  The Chair thanked those present for attending and closed the meeting.  <b><u>NOTED</u></b>		
<b>09.</b>	<b>DATE OF NEXT SCHEDULED MEETING</b>		
	Monday 24 <sup>th</sup> April 2023 at 2pm via MS Teams.		